375 related articles for article (PubMed ID: 32493790)
1. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia.
Vadakekolathu J; Minden MD; Hood T; Church SE; Reeder S; Altmann H; Sullivan AH; Viboch EJ; Patel T; Ibrahimova N; Warren SE; Arruda A; Liang Y; Smith TH; Foulds GA; Bailey MD; Gowen-MacDonald J; Muth J; Schmitz M; Cesano A; Pockley AG; Valk PJM; Löwenberg B; Bornhäuser M; Tasian SK; Rettig MP; Davidson-Moncada JK; DiPersio JF; Rutella S
Sci Transl Med; 2020 Jun; 12(546):. PubMed ID: 32493790
[TBL] [Abstract][Full Text] [Related]
2. Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells.
Rimando JC; Chendamarai E; Rettig MP; Jayasinghe R; Christopher MJ; Ritchey JK; Christ S; Kim MY; Bonvini E; DiPersio JF
Blood; 2023 Apr; 141(14):1718-1723. PubMed ID: 36563336
[TBL] [Abstract][Full Text] [Related]
3. TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML.
Vadakekolathu J; Lai C; Reeder S; Church SE; Hood T; Lourdusamy A; Rettig MP; Aldoss I; Advani AS; Godwin J; Wieduwilt MJ; Arellano M; Muth J; Yau TO; Ravandi F; Sweet K; Altmann H; Foulds GA; Stölzel F; Middeke JM; Ciciarello M; Curti A; Valk PJM; Löwenberg B; Gojo I; Bornhäuser M; DiPersio JF; Davidson-Moncada JK; Rutella S
Blood Adv; 2020 Oct; 4(20):5011-5024. PubMed ID: 33057635
[TBL] [Abstract][Full Text] [Related]
4. Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukemia.
Laing AA; Harrison CJ; Gibson BES; Keeshan K
Exp Hematol; 2017 Oct; 54():40-50. PubMed ID: 28668350
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in acute myeloid leukemia.
Grosso DA; Hess RC; Weiss MA
Cancer; 2015 Aug; 121(16):2689-704. PubMed ID: 26095886
[TBL] [Abstract][Full Text] [Related]
6. The potential role of Bi-specific antibodies in acute myeloid leukemia.
Yilmaz M; Ravandi F
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101218. PubMed ID: 33279174
[TBL] [Abstract][Full Text] [Related]
7. Dissecting the Immune Landscape of Acute Myeloid Leukemia.
Davidson-Moncada J; Viboch E; Church SE; Warren SE; Rutella S
Biomedicines; 2018 Nov; 6(4):. PubMed ID: 30477280
[TBL] [Abstract][Full Text] [Related]
8. Molecularly targeted therapy in acute myeloid leukemia.
Gill H; Leung AY; Kwong YL
Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies.
Chen EC; Garcia JS
Acta Haematol; 2024; 147(2):198-218. PubMed ID: 37673048
[TBL] [Abstract][Full Text] [Related]
10. Bispecific Antibodies for the Treatment of Acute Myeloid Leukemia.
Guy DG; Uy GL
Curr Hematol Malig Rep; 2018 Dec; 13(6):417-425. PubMed ID: 30280288
[TBL] [Abstract][Full Text] [Related]
11. [Regulation Effect of Myeloid Leukemia No.1 Chinese Herb Medicine Prescription Combined with Chemotherapy on Th17 Cells in Bone Marrow of Patients with Acute Myeloid Leukemia].
Zhang GL; Pan M; Wang YZ; Huang JX; Gu GS; Wang Y; Wu Q; Yao LT; Xie HR; Hu XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):328-332. PubMed ID: 33812395
[TBL] [Abstract][Full Text] [Related]
12. Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia.
Gurnari C; Pagliuca S; Visconte V
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198085
[TBL] [Abstract][Full Text] [Related]
13. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
Leong SR; Sukumaran S; Hristopoulos M; Totpal K; Stainton S; Lu E; Wong A; Tam L; Newman R; Vuillemenot BR; Ellerman D; Gu C; Mathieu M; Dennis MS; Nguyen A; Zheng B; Zhang C; Lee G; Chu YW; Prell RA; Lin K; Laing ST; Polson AG
Blood; 2017 Feb; 129(5):609-618. PubMed ID: 27908880
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens.
Luo W; Yu H; Zou X; Ni X; Wei J
Cancer Biomark; 2018; 23(4):485-494. PubMed ID: 30347595
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
Bose P; Vachhani P; Cortes JE
Curr Treat Options Oncol; 2017 Mar; 18(3):17. PubMed ID: 28286924
[TBL] [Abstract][Full Text] [Related]
16. Progress in the problem of relapsed or refractory acute myeloid leukemia.
Mims AS; Blum W
Curr Opin Hematol; 2019 Mar; 26(2):88-95. PubMed ID: 30640734
[TBL] [Abstract][Full Text] [Related]
17. Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML.
Mahalleh M; Shabani M; Rayzan E; Rezaei N
Immunotherapy; 2019 Dec; 11(18):1583-1600. PubMed ID: 31841068
[TBL] [Abstract][Full Text] [Related]
18. Pediatric acute myeloid leukemia: Insight into genetic landscape and novel targeted approaches.
Tosic N; Marjanovic I; Lazic J
Biochem Pharmacol; 2023 Sep; 215():115705. PubMed ID: 37532055
[TBL] [Abstract][Full Text] [Related]
19. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
Naqvi K; Konopleva M; Ravandi F
Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
[TBL] [Abstract][Full Text] [Related]
20. Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia.
Walter RB
Expert Rev Hematol; 2014 Jun; 7(3):317-9. PubMed ID: 24617311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
